# Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection

> **NCT06734260** · PHASE3 · RECRUITING · sponsor: **Eighth Affiliated Hospital, Sun Yat-sen University** · enrollment: 477 (estimated)

## Conditions studied

- Helicobacter Pylori Eradication Rate

## Interventions

- **DRUG:** Keverprazan Hydrochloride tablets + high dose amoxicillin
- **DRUG:** Keverprazan Hydrochloride tablets + low dose amoxicillin
- **DRUG:** Keverprazan Hydrochloride tablets + high dose amoxicillin（H-KA-10d）

## Key facts

- **NCT ID:** NCT06734260
- **Lead sponsor:** Eighth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2025-11-10
- **Final completion:** 2026-01-10
- **Target enrollment:** 477 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06734260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06734260, "Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06734260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*